Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 18, 2023 08:03 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates

uBriGene (Boston) Biosciences to acquire Mustang Bio’s Worcester manufacturing facility for total consideration of up to $11 million and enters into strategic manufacturing partnership to support...
May 12, 2023 16:05 ET | Source: Mustang Bio, Inc.

Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

WORCESTER, Mass., May 12, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
May 11, 2023 16:03 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy

Data from Waldenstrom macroglobulinemia cohort selected for poster presentation at EHA2023 Outpatient treatment of follicular lymphoma selected for oral presentation at ICML WORCESTER, Mass., May ...
April 03, 2023 12:15 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Reverse Stock Split

WORCESTER, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...
March 29, 2023 16:15 ET | Source: Mustang Bio, Inc.

Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

WORCESTER, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
March 28, 2023 08:30 ET | Source: Mustang Bio, Inc.

Mustang Bio to Participate in Cantor’s The Future of Oncology Virtual Symposium

WORCESTER, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...
January 17, 2023 08:15 ET | Source: Mustang Bio, Inc.

Mustang Bio to Participate in the B. Riley Securities’ 3rd Annual Oncology Conference

WORCESTER, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...
December 19, 2022 08:30 ET | Source: Mustang Bio, Inc.

Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones

MB-106 clinical trial under Mustang’s IND continues to enroll patients Additional IND filing and published research expected in 2023 across portfolio WORCESTER, Mass., Dec. 19, 2022 (GLOBE...
November 14, 2022 16:05 ET | Source: Mustang Bio, Inc.

Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

WORCESTER, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
October 27, 2022 08:00 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia

MB-106 demonstrated 100% overall response rate in Waldenstrom macroglobulinemia Data to be presented by Fred Hutch’s Dr. Mazyar Shadman WORCESTER, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) --...